Drug Type Monoclonal antibody |
Synonyms SEA-TGT, SGN TGT, SEA TGT + [2] |
Target |
Action inhibitors |
Mechanism TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |




| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | United States | 29 May 2020 | |
| Advanced cancer | Phase 1 | Canada | 29 May 2020 | |
| Advanced cancer | Phase 1 | France | 29 May 2020 | |
| Advanced cancer | Phase 1 | Italy | 29 May 2020 | |
| Advanced cancer | Phase 1 | Spain | 29 May 2020 | |
| Advanced cancer | Phase 1 | United Kingdom | 29 May 2020 | |
| Bladder Cancer | Phase 1 | United States | 29 May 2020 | |
| Bladder Cancer | Phase 1 | Canada | 29 May 2020 | |
| Bladder Cancer | Phase 1 | France | 29 May 2020 | |
| Bladder Cancer | Phase 1 | Italy | 29 May 2020 |
NCT04254107 (AACR2023) Manual | Phase 1 | 39 | kzvsdldktt(oqgfljcfmx) = ewunaddrnq lyirxyilpq (ymavpfmbbs ) View more | Positive | 14 Apr 2023 |






